Doug Reed, PhD
3501 Fifth Avenue
Pittsburgh, Pennsylvania 15261
Phone: (412) 648-1922
Beary, Megan Elizabeth
Bowling, Jennifer Dianne
CVR - RBLDSI
Midgett, Morgan L
Reed, Douglas S
Willett, Katherine Jean
Dr. Reed did his doctoral work at the University of Texas Southwestern Medical Center at Dallas, working on thymocyte development in vitro. In 1995 Dr. Reed completed his dissertation and moved to Connecticut, where he worked as a postdoctoral fellow in the laboratory of Dr. Leo Lefrancois studying T lymphocyte activation in response to antigens entering through the small intestine. Dr. Reed became a principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in 1999, developing animal models to aerosolized pathogens and testing medical countermeasures in those models. While at USAMRIID Dr. Reed conducted and supervised aerosol exposures of animals including rodents, rabbits, and nonhuman primates. Dr. Reedís research at USAMRIID included developing nonhuman primate models of aerosol exposure to Venezuelan, Western, and Eastern Equine Encephalitis and evaluating candidate vaccines in those models, developing rodent and nonhuman primate (NHP) models of aerosol exposure to Marburg and Ebola viruses, and evaluating a GMP-grade recombinant plague vaccine in mice against pneumonic plague. In 2008 Dr. Reed moved to University of Pittsburgh to work in the Regional Biocontainment Laboratory. At Pittsburgh he has developed a rabbit model of pneumonic tularemia and is using that model to evaluate new vaccines and determine immunological correlates of protection. In collaboration with Dr. Amy Hartman he has developed the first reproducibly lethal NHP models of Rift Valley Fever and with Dr. Kate Ryman and Dr. William Klimstra is continuing his work on the encephalitic alphaviruses.
Dr. Reedís research interests can be grouped into 2 main categories: the first category is the host immune response to pneumonic tularemia and immune mechanisms of protection. Tularemia, also known as rabbit fever, is an acute disease marked by severe morbidity and mortality. Tularemia is caused by a gram negative bacterium, Francisella tularensis. Inhalation of as few as 15 organisms is sufficient to cause disease. No licensed vaccine exists but because there is the potential that F. tularensis could be used as a biological weapon, a vaccine is urgently needed. At the University of Pittsburgh, Dr. Reed has re-established the rabbit as a model of human pneumonic tularemia. Working with Dr. Eileen Barry from the University of Maryland, they have demonstrated that recombinant derivatives of a virulent F. tularensis are attenuated and potential vaccine candidates that provide good protection in the rabbit model. With the addition of a second collaborator, Dr. Karsten Hazlett of Albany Medical College, they have demonstrated that the serum antibody response to F. tularensis is a potential correlate of protection. They were recently awarded a five year, multi-PI R01 grant to explore the immune mechanisms responsible for the protection seen in the rabbit model. The second category involves the development of animal models for aerosol exposure to infectious agents and using those models to understand the pathogenesis of those agents and to evaluate the efficacy of candidate vaccines and therapeutics. Aerosol dissemination is the most likely route of dissemination of viruses and bacteria considered as potential bioterrorism threats. Biodefense pathogens cause significant morbidity and mortality when inhaled but aerosol is not a natural route of transmission for most biodefense pathogens. Dr. Reed is an expert with 16 years of experience in exposing animals to small particle aerosols containing pathogenic agents. Dr. Reed has led or participated in the development of nonhuman primate models for aerosol exposure to a number of highly pathogenic viruses including Highly Pathogenic Avian Influenza (HPAI), Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), eastern equine encephalitis virus (EEEV), and Rift Valley Fever virus (RVFV). Dr. Reed has used radiotelemetry to study physiological responses to a number of acute infections including alphaviruses, filoviruses, anthrax, plague, and RVF. He has utilized mathematical modeling to quantitate fever responses and used that data to evaluate medical countermeasures when prevention of morbidity, not mortality, was critical in determining efficacy. Using this modeling of febrile responses in nonhuman primates, he was successful in demonstrating the efficacy of potential vaccines for VEEV. This work was critical in the selection of a VEEV vaccine candidate for advancement into clinical trials. In recognition of this work Dr. Reed was awarded the U.S. Armyís Research & Development Achievement Award for Technical Excellence in 2003.
- Stinson. E., Smith, L.P., Cole. K.S., Barry, E.M., Reed, D.S. In Press. Respiratory and oral vaccination improves protection conferred by the Live Vaccine Strain against pneumonic tularemia in the rabbit model. Pathog. Dis.
- Cadena, A.M., Klein, E., White, A.G., Tomko, J., Reed, D.S., Chedrick, C.L., Via, L.E,. Lin, P.L., Flynn, J.L. In Press. Very low dose infection with Mycobacterium tuberculosis results in a spectrum of host outcomes in the common marmoset (Callithrix jacchus). Comp. Med.
- Abdelbaqi, S., Deslouches, B., Steckbeck, J., Montelaro, R., Reed, D.S. 2016. Novel engineered cationic antimicrobial peptides have a broad-spectrum activity against Francisella tularensis, Yersinia pestis, and Burkholderia pseudomallei. J. Med Microbiol. 65(2):188-94 PMID: 26673248
- Caroline, A.C., Kujawa, M.R, Oury, T., Reed, D.S., Hartman, A.L. 2016. Inflammatory biomarkers associated with lethal Rift Valley fever encephalitis in the Lewis rat model. Front Microbiol Immunol. 6:1509 doi: 10.3389/fmicb.2015.01509 PMID: 26779164
- Reed, D.S.*, Glass, P.J.*, Bakken, R.R., Barth, J.F., Lind, C.M., Hart, M.K., Rayner, J., Alterson, K., Custer, M., Dudek, J., Owens, G., Kamrud, K.I., Parker, M.D., Smith, J. 2014. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitic viruses. J. Virol. 88(20):12077-86 PMID: 25122801 *- equal contribution
- Reed, D.S., Smith, L., Cole, K.S., Santiago, A.E., Mann, B.J., Barry, E.M. 2014. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Infect Immun 82(5):2098-2105 PMID: 24614653
- Caroline, A.L., Powell, D.S., Bethel, L.M., Oury, T.D., Reed, D.S., Hartman, A.L. 2014. Broad spectrum antiviral activity of Favipiravir (T-705): Protection from highly lethal inhalational Rift Valley Fever in Wistar-Furth rats. PLoS Negl Trop Dis 8(4):e2790 PMID: 24722586
- Hartman, A.L., Powell, D.S., Bethel, L.M., Caroline, A.L., Schmid, R.J., Oury, T., Reed, D.S. 2014. Aerosolized Rift Valley Fever virus causes fatal encephalitis in African green monkeys and common marmosets. J. Virol. 88(4):2235-2245. PMID: 24335307
- Faith, S.A., Smith, L.P., Swatland, A.S., Reed, D.S. 2012. Growth conditions and environmental factors impact aerosolization but not virulence of Francisella tularensis infection in mice. Front Cell Inf Microbio. 2(126):1-10. PMID: 23087911
- Reed, D.S., Smith, L., Dunsmore, T., Trichel, A., Ortiz, L.A., Cole, K.S., Barry, E. 2011. Pneumonic tularemia in rabbits resembles the human disease as illustrated by radiographic and hematological changes after infection. PLoS One. 6(9):1-9. PMID: 21931798